Market access and communications

  • Payer insights for cell and gene therapies2:29

    Payer insights for cell and gene therapies

    It is essential to address the payer landscape very early in development for a product administered once with a lifelong effect, such as a gene therapy. The one-time, front-loaded costs of these treat

    Watch Video
  • Maximizing your virtual investigator meeting results2:28

    Maximizing your virtual investigator meeting results

    Learn how Parexel brings the principles and energy from face-to-face investigator meetings to an interactive and engaging virtual environment.

    Watch Video
  • Impact of Real-World Evidence on Payers & Patients3:29

    Impact of Real-World Evidence on Payers & Patients

    Dr. Scott Gottlieb, Former Commissioner of the Food and Drug Administration speaks with Parexel’s Peyton Howell, Executive Vice President, Chief Commercial & Strategy Officer and Sy Pretorius, Executi

    Watch Video
  • Real-World Evidence: The Feedback Loop3:18

    Real-World Evidence: The Feedback Loop

    RWE experts Leanne Larson, Senior Vice President and Worldwide Head, Real-World Evidence and Access and Amy McKee, Vice President, Regulatory and Access dig deeper into the evolving role of RWE.

    Watch Video
  • Navigating the new normal for meetings – now and for the future

    Navigating the new normal for meetings – now and for the future

    View Now
  • ×

    Speak to one of our experts today

    First Name
    Last Name
    Company Name
    Title
    Country
    Tell us how we can help
    We'll be in touch shortly!
    Error - something went wrong!
  • ×

    Register now for full access to all the content

    First Name
    Last Name
    Company Name
    Title
    Country
    Thank you for registering!
    Error - something went wrong!
  • Virtual meetings are easy, right?

    Virtual meetings are easy, right?

    Recommendations for navigating the "new normal" and how to prepare for the future.

    Learn More
  • EMA Guidance: Management of Clinical Trials - What it means for Patients?

    EMA Guidance: Management of Clinical Trials - What it means for Patients?

    A lay summary for patients participating in clinical trials

    View Now
  • Putting the Pandemic in Plain Language

    Putting the Pandemic in Plain Language

    The COVID-19 pandemic has brought many negative feelings to the forefront of our everyday lives, including anxiety, fear and social division, but what if we explored the new positive relationships...

    Learn More
  • CAR-T: How far have we come and where are we going?

    CAR-T: How far have we come and where are we going?

    In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days....

    Learn More
  • Parexel Regulatory & Access Overview Brochure

    Parexel Regulatory & Access Overview Brochure

    View Now
  • How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance

    How the UK's HTA Agency Uses Real-World Evidence to Develop Guidance

    The UK national health technology assessment (HTA) body, the National Institute for Health and Clinical Excellence (NICE), made a long-awaited announcement last week: NICE has expanded the...

    Learn More
  • Press announcement: Parexel unveils combined Regulatory & Access consulting organization

    Press announcement: Parexel unveils combined Regulatory & Access consulting organization

    Learn More
  • Interview with Paul Bridges, Head of R&A

    Interview with Paul Bridges, Head of R&A

    If regulatory and payer landscapes are so different, then why bring the two worlds together?

    View Now
  • Reimagining The Global Value Dossier - Part 6

    Reimagining The Global Value Dossier - Part 6

    A clear value strategy is key to the success of any product attempting to enter the healthcare market; defining the right strategy should lead to the perfect positioning for your product and...

    Learn More
  • Commercial and Regulatory Strategy Considerations for Biotech

    Commercial and Regulatory Strategy Considerations for Biotech

    Many critical and innovative new therapies today, including those for rare and untreated diseases, are in the biotech pipeline. In fact, today biotech represents more than 80 percent of the...

    Learn More
  • Use Real-World Evidence to Navigate From Regulatory Approval to Reimbursement Success

    Use Real-World Evidence to Navigate From Regulatory Approval to Reimbursement Success

    Use Real-World Evidence to Navigate From Regulatory Approval to Reimbursement Success

    View Now
  • How to align your market access activities with your product value strategy

    How to align your market access activities with your product value strategy

    The value strategy (also termed value story) for your product should act as the cornerstone for all market access activities.  The value strategy drives your market access planning, which...

    Learn More
  • Reimagining the Global Value Dossier - Part 4

    Reimagining the Global Value Dossier - Part 4

    Health Technology Assessment (HTA) agencies are increasingly demanding the inclusion of patient-relevant data in submission dossiers. It is evident that there is an effort to ensure...

    Learn More
  • Commercializing Gene and Cellular Therapy

    Commercializing Gene and Cellular Therapy

    Gene and cellular therapy manufacturing requires strict control in current Good Manufacturing Practice (cGMP) facilities.  Designing a facility or finding a contract manufacturer to meet the...

    Learn More
  • Capturing the patient voice in market access communications

    Capturing the patient voice in market access communications

    Patients have unique perspectives on their conditions that, when incorporated into value communications, can provide an authenticity and salience which would otherwise be lacking. Who knows...

    Learn More
  • loading
    Loading More...